Citation for final published version:


Publishers page: http://dx.doi.org/10.1016/j.jhep.2016.07.045

Please note:
Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher’s version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.
The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans

To the Editor:
We have recently shown in 125 subjects that insulin resistance and the PNPLA3 I148M gene variant, two common risk factors of NAFLD, are characterized with markedly different content and composition of lipids in the human liver [1]. In 2015, a variant in membrane bound O-acyltransferase domain containing 7 (MBOAT7) at rs641738 was discovered to increase the risk of alcohol-related cirrhosis [2]. This variant was also shown to increase the risk of steatosis and histologic liver damage in NAFLD, independent of obesity [3]. The variant allele was common with a population prevalence of 58–67% and characterized by decreased hepatic gene and protein expression of MBOAT7 [3]. MBOAT7 is also known as lysophosphatidylinositol acyltransferase 1 (LPIAT1), which catalyzes acyl-chain remodeling of phosphatidylinositols (PIs) [4]. Consistent with this function, plasma lipidomics analyses showed that amongst various lipid classes (triglycerides, cholesterol esters, phospholipids, ceramides and sphingomyelins), only concentrations of PIs were altered [3]. Specifically, plasma concentrations of PI (36:4), PI (38:3) and PI (38:5) were decreased in proportion to the number of MBOAT7 variant alleles, while most other PIs were increased [3].

To study effects of genetic variation in MBOAT7 on human liver histology and lipidome, we genotyped the subjects in our previous study at rs641738 [1]. The subjects were consecutive patients undergoing bariatric surgery recruited using the inclusion and exclusion criteria described in [1]. The liver lipidome was analyzed using ultra-high-performance liquid and gas chromatography combined with mass spectrometry and histology as described [1]. DNA was available from 115 subjects (age 48.0 ± 8.8 years, BMI 45.4 ± 0.5 kg/m², 67% women), who were divided into three groups based on their MBOAT7 genotype at rs641738 (n = 35 for CC, n = 60 for CT, n = 20 for TT).

The MBOAT7 genotype groups were similar with respect to age, gender, BMI, waist circumference, PNPLA3 I148M and TM6SF2 E167K genotypes (data not shown).

Steatosis (% of grades 0/1/2/3 were 23/60/3/14, 25/62/12/2 and 20/55/25/0, p = 0.03 in CC, CT and TT groups) and necroinflammatoryity (% of grades 0/1/2/3 were 74/26/0/0, 87/13/0/0 and 60/35/0/5, p = 0.04) grades differed significantly between the MBOAT7 groups. The prevalence of significant fibrosis (F2–4) increased with number of MBOAT7 variant alleles (0 vs. 5 vs. 25%, p = 0.001, Fig. 1). Of 7 different PIs in the human liver, PI (36:4) and PI (38:3), i.e., the same PIs as in the plasma in the study of Mancina and Dongiovanni et al. [3], decreased significantly as a function of the number of MBOAT7 variant alleles, while the concentration of PI (40:5) increased (Fig. 1). All other lipid classes in the human liver (triglycerides, cholesterol esters, ceramides, sphingomyelins, hexosylceramides, phospholipids, and free fatty acids) were similar between the groups (data not shown). Fasting insulin (13.7 [8.4–17.1], 11.2 [6.5–18.3] and 12.3 [7.0–18.8] mU/L in CC, CT and TT groups), glucose (5.9 [5.0–6.6], 5.8 [5.4–6.6] and 5.7 [5.1–6.1] mmol/L), triglycerides (1.24 [1.06–1.55], 1.29 [0.91–1.69] and 1.08 [1.00–1.59] mmol/L), HDL (1.15 [0.98–1.33], 1.09 [0.93–1.38] and 0.98 [0.86–1.13] mmol/L) and low density lipoprotein (2.5 [1.9–3.4], 2.3 [1.7–2.9] and 2.4 [1.5–3.5] mmol/L) cholesterol concentrations were similar between the groups.

We thus replicate effects of the MBOAT7 variant rs641738 on human liver histology with respect to steatosis and necroinflammation, and an increased prevalence of significant fibrosis [3]. The latter is the key predictor of overall mortality, liver transplantation, and liver-related events [5,6].

Pls are lipids, which regulate membrane dynamics and signal transduction pathways [4]. They consist of a glycerol backbone and two variable fatty acyl-chains, of which one is predominantly saturated and the other polyunsaturated [4]. MBOAT7 participates in acyl-chain remodeling of Pls in the Land’s cycle, in which it incorporates a polyunsaturated fatty acyl-chain into a P [4]. In mice, knockout of LPIAT1, i.e., MBOAT7, affects concentrations of hepatic polyunsaturated PIs [7]. Another enzyme of the MBOAT family, MBOAT5, participates in the acyl-chain remodeling of phosphatidylincholines [8]. Knockout of MBOAT5 in mice decreases arachidonic acid-containing phosphatidylincholines in the liver and increases the risk of hepatic steatosis and inflammation [8]. MBOAT7 deficiency is thus predicted to increase free polyunsaturated fatty acids [9] and their proinflammatory metabolites, which are increased in plasma of subjects with non-alcoholic steatohepatitis [10]. Detailed understanding of the mechanisms via which the altered hepatic phosphatidylinositol metabolism leads to liver fibrosis are thus of considerable interest.

In conclusion, we confirm that the common variant in MBOAT7 rs641738 associates with histologic liver damage, particularly significant fibrosis. We extend previous data by showing that altered polyunsaturated Pl metabolism characterizes the human liver in carriers of the MBOAT7 variant. These data are consistent with recent data in plasma and a role for MBOAT7 in hepatic phosphatidylinositol remodeling [3].

Financial support
This study was supported by research grants from the Academy of Finland (HY), EU H2020 EpoS 634413 (HY), the Sigrid Juselius (HY) and EVO (HY) Foundations.

Conflict of interest
The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.
Letter to the Editor

![Figure 1. Prevalence of significant fibrosis and hepatic concentrations of phosphatidylinositols PI (40:5), PI (36:4), and PI (38:3) in groups according to the MBOAT7 genotype at rs641738. Data are in % and median (25th–75th percentile), and were tested using Pearson’s χ² test, Kolmogorov-Smirnov test and Mann-Whitney U test as appropriate. *p <0.05, **p <0.01.](image)

**Authors’ contributions**

PL – study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; statistical analysis. YZ, TH, ML, JA, MOM, MO – acquisition of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; obtained funding; study supervision.

**Acknowledgements**

We thank Anne Salo, Aila Karioja-Kallio, Mia Urjansson, Katja Sohol, Erja Juvonen, Anna-Liisa Ruskeepää, Ulla Lahtinen, Heli Nygren and Ismo Mattila for their excellent technical assistance.

**References**

*Author names in bold designate shared co-first authorship*


Panu K. Luukkonen1,7,∗
You Zhou1,6,7
Tuulia Hyytyläinen5
Marja Leivonen2
Johanna Arola3
Marju Orho-Melander4
Matej Orešič5
Hannele Yki-Järvinen1,7

1Department of Medicine, University of Helsinki, Helsinki University Hospital, Helsinki, Finland
2Department of Surgery, University of Helsinki, Helsinki University Hospital, Helsinki, Finland
3Department of Pathology, University of Helsinki, Helsinki University Hospital, Helsinki, Finland
4University of Lund, Malmö, Sweden
5Steno Diabetes Center, Gentofte, Denmark
6Systems Immunity University Research Institute and Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom
7Minerva Foundation Institute for Medical Research, Helsinki, Finland

*Corresponding author. Address: University of Helsinki and Helsinki University Hospital, Department of Medicine, Tukholmankatu 8, 00290 Helsinki, Finland.
Tel.: +358 2 9412 5708; fax: +358 9 4717 1896.
E-mail address: panu.luukkonen@fimnet.fi